Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.
Jerome Galon, PhD
Advertisement
Articles by Jerome Galon, PhD
Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.
Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.
Jerome Galon, PhD, research director, Institut National de la Santé et de la Recherche Médicale, discusses the prognostic value of the Immunoscore assay and its corresponding validation study, which was presented during the 2016 ASCO Annual Meeting.
Advertisement
Latest Updated Articles
Jerome Galon on the Prognostic Value of ImmunoscorePublished: June 16th 2016 | Updated:
The Clinical Utility of Immunoscore in Stage III CRCPublished: June 14th 2019 | Updated:
Expanding the Use of Immunoscore in Early-Stage CRCPublished: June 20th 2019 | Updated:
Next Steps for Immunoscore in OncologyPublished: October 10th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5